The National Cancer Institute’s Small Business Innovation Research (NCI SBIR) Development Center provides funding, networking, and mentoring assistance to small businesses with early-stage innovative cancer technology projects. During this Texas Medical Center Accelerator for Cancer Therapeutics (TMC ACT) webinar, NCI SBIR Team Leader Greg Evans and Program Directors Christie Canaria and Nancy Kamei will present funding opportunities and commercialization resources for entrepreneurs and small businesses Exit Disclaimer.
This presentation is appropriate for both established and emerging entrepreneurs in small businesses or academia interested in moving life science technologies to patients and/or marketplace.
The presentation will cover the following topics:
• Overview of SBIR/STTR eligibility requirements
• New and existing funding opportunities from NIH and NCI
• Resources such as the I-Corps at NIH Program and Applicant Assistance Program
• Initiatives to help NCI SBIR-funded companies to connect with investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries
• Practical strategies on how to successfully submit competitive research proposals
TMC ACT is the only cancer therapeutics accelerator building relationships with health care professionals leading the world’s best cancer treatment programs at the Texas Medical Center member hospitals. The ACT accelerator program is funded by the Cancer Prevention and Research Institute of Texas (CPRIT) in collaboration with the Gulf Coast Consortium (GCC) and the University of Texas Medical Branch (UTMB) to support Texas-based biotech entrepreneurs, researchers contemplating translations, and internal comprehensive drug development programs.
ACT is a comprehensive nine-month program designed to enhance oncology biotech entrepreneurship training and drug development programs in Texas. ACT will simultaneously provide Texas researchers and startup companies with integrated training, resources, and mentoring in order to help advance innovative cancer therapy discoveries and development programs, ultimately leading to new approaches and therapies for cancer patients.